Garrett Baldwin gives a sneak peek at what's coming for the markets as we draw closer to winter.
XBI
S&P Biotech SPDR
How to Profit in a $29 Billion “New Biotech” Sector
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Back in the late 1960s and early 1970s, psychedelics drugs like LSD were still legal and could be researched.
But in 1968 when the federal government criminalized them, a lot of promising research stopped.
Now the spotlight is back on these drugs and the success they’ve shown in clinical trials for treating a range of mental health conditions.
This is not only great news for people suffering from these conditions, but also for savvy investors who’ll get in on the ground floor of a market that could be worth more than $29 billion by the end of the decade.
Here’s Shah with all the details….
There's Still Some Time to Move on This Must-Own Biotech
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Some market-leading biotech firms are working hard right now developing drugs derived from cannabis' many beneficial compounds.
And there's one innovative company that puts you right in the middle of the sector's market-crushing gains.
Plus, there's still some time left to get in and grab the profits….
Instead of Chasing Every New Vaccine "Breakthrough," Trade the Whole Sector
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Not every biotech company is doing well in the search for an effective COVID-19 vaccine or treatment.
And the latest firm to struggle is Eli Lilly, whose antibody clinical trial was paused due to failure to show any real results.
So today, Andrew's going to show you a much more profitable move to make instead of chasing every vaccine "breakthrough" news…
The Dow Jones Today Will Lose Hundreds of Points as China Raises Tariffs
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
The Dow Jones today will plummet as China plans its own tariff hike on $60 billion of U.S. goods starting June 1.
This is the latest intensification of a trade war between the countries.
Let's Buy the Real Breakout in the Soaring Tech Sector
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
The tech sector has been having a field day lately, and our Chris Johnson is back with his latest "Best in Breed" focus: biotech.
Find out how the numbers don't lie when it comes to this sector...
The 3 Best Biotech Stocks to Buy for 2018
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Investors looking for profits in the healthcare sector had a difficult time in 2017 if they weren't in biotech. The Health Care SPDR ETF only gained 13.15% last year, while the S&P 500 climbed 22.5% over the same time period.
But within the broader health care sector the SPDR S&P Biotech ETF returned a market-beating 43.36% in 2017, nearly double the broader S&P 500.
That's why today we'll show you the three best biotech stocks to buy for 2018.
Best ETF Performers of the Week (June 19-23, 2017)
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Here's a look at the best ETF performers for the week of June 19-23, 2017.
Biotech dominated the list, with four of the top 10 performers.
Inverse energy funds and gold mining ETFs rounded out the list.
Start the conversation